Vertex Pharmaceuticals Net Income
| VRTX Stock | USD 477.89 3.62 0.76% |
As of the 5th of March, Vertex Pharmaceuticals has the Semi Deviation of 1.37, coefficient of variation of 1165.58, and Risk Adjusted Performance of 0.0708. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them.
Vertex Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 9.9065 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 4 B | 4.2 B | |
| Net Income From Continuing Ops | 4 B | 4.2 B | |
| Net Income Applicable To Common Shares | 3.8 B | 4 B | |
| Net Income Per Share | 15.46 | 16.23 | |
| Net Income Per E B T | 0.85 | 0.64 |
Vertex | Net Income | Build AI portfolio with Vertex Stock |
The evolution of Net Income for Vertex Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vertex Pharmaceuticals compares to historical norms and industry peers.
Latest Vertex Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Vertex Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vertex Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Vertex Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vertex Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 3.95 B | 10 Years Trend |
|
Net Income |
| Timeline |
Vertex Net Income Regression Statistics
| Arithmetic Mean | 1,245,031,882 | |
| Coefficient Of Variation | 142.98 | |
| Mean Deviation | 1,586,015,626 | |
| Median | 263,484,000 | |
| Standard Deviation | 1,780,092,133 | |
| Sample Variance | 3168728T | |
| Range | 4.9B | |
| R-Value | 0.76 | |
| Mean Square Error | 1404214.9T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | 269,514,924 | |
| Total Sum of Squares | 50699648T |
Vertex Net Income History
Other Fundumenentals of Vertex Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vertex Pharmaceuticals Net Income component correlations
Vertex Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Vertex Stock properly, considering its historical fundamentals such as Net Income. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vertex Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.329 | Earnings Share 15.32 | Revenue Per Share | Quarterly Revenue Growth 0.095 | Return On Assets |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Vertex Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Vertex Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vertex Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vertex Pharmaceuticals.
| 12/05/2025 |
| 03/05/2026 |
If you would invest 0.00 in Vertex Pharmaceuticals on December 5, 2025 and sell it all today you would earn a total of 0.00 from holding Vertex Pharmaceuticals or generate 0.0% return on investment in Vertex Pharmaceuticals over 90 days. Vertex Pharmaceuticals is related to or competes with McKesson, HCA Holdings, Medtronic PLC, Sanofi ADR, Regeneron Pharmaceuticals, GlaxoSmithKline PLC, and Bristol Myers. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for tr... More
Vertex Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vertex Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vertex Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.48 | |||
| Information Ratio | 0.0638 | |||
| Maximum Drawdown | 9.91 | |||
| Value At Risk | (2.49) | |||
| Potential Upside | 4.31 |
Vertex Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vertex Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vertex Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Vertex Pharmaceuticals historical prices to predict the future Vertex Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0708 | |||
| Jensen Alpha | 0.1327 | |||
| Total Risk Alpha | 0.0709 | |||
| Sortino Ratio | 0.0866 | |||
| Treynor Ratio | 0.189 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vertex Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vertex Pharmaceuticals March 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0708 | |||
| Market Risk Adjusted Performance | 0.199 | |||
| Mean Deviation | 1.49 | |||
| Semi Deviation | 1.37 | |||
| Downside Deviation | 1.48 | |||
| Coefficient Of Variation | 1165.58 | |||
| Standard Deviation | 2.0 | |||
| Variance | 4.02 | |||
| Information Ratio | 0.0638 | |||
| Jensen Alpha | 0.1327 | |||
| Total Risk Alpha | 0.0709 | |||
| Sortino Ratio | 0.0866 | |||
| Treynor Ratio | 0.189 | |||
| Maximum Drawdown | 9.91 | |||
| Value At Risk | (2.49) | |||
| Potential Upside | 4.31 | |||
| Downside Variance | 2.18 | |||
| Semi Variance | 1.89 | |||
| Expected Short fall | (1.87) | |||
| Skewness | 1.13 | |||
| Kurtosis | 1.72 |
Vertex Pharmaceuticals Backtested Returns
At this stage we consider Vertex Stock to be very steady. Vertex Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0519, which indicates the firm had a 0.0519 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Vertex Pharmaceuticals, which you can use to evaluate the volatility of the company. Please validate Vertex Pharmaceuticals' Coefficient Of Variation of 1165.58, semi deviation of 1.37, and Risk Adjusted Performance of 0.0708 to confirm if the risk estimate we provide is consistent with the expected return of 0.0971%. Vertex Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The entity has a beta of 0.86, which indicates possible diversification benefits within a given portfolio. Vertex Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Vertex Pharmaceuticals is expected to follow. Vertex Pharmaceuticals right now has a risk of 1.87%. Please validate Vertex Pharmaceuticals value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to decide if Vertex Pharmaceuticals will be following its existing price patterns.
Auto-correlation | -0.14 |
Insignificant reverse predictability
Vertex Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Vertex Pharmaceuticals time series from 5th of December 2025 to 19th of January 2026 and 19th of January 2026 to 5th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vertex Pharmaceuticals price movement. The serial correlation of -0.14 indicates that less than 14.0% of current Vertex Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.14 | |
| Spearman Rank Test | 0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 111.68 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vertex Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vertex Pharmaceuticals reported net income of 3.95 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.
Vertex Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in net income category among its peers.
Vertex Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Vertex Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.| Shares | Jennison Associates Llc | 2025-12-31 | 3.2 M | Norges Bank | 2025-12-31 | 3.2 M | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 3.1 M | T. Rowe Price Associates, Inc. | 2025-09-30 | 3 M | Ubs Asset Mgmt Americas Inc | 2025-09-30 | 2.9 M | Bank Of America Corp | 2025-09-30 | 2.8 M | Clearbridge Advisors, Llc | 2025-09-30 | 2.6 M | Northern Trust Corp | 2025-09-30 | 2.6 M | Ameriprise Financial Inc | 2025-09-30 | 2.3 M | Capital World Investors | 2025-09-30 | 25.9 M | Vanguard Group Inc | 2025-12-31 | 24.1 M |
Vertex Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.33 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 118.89 B | ||||
| Shares Outstanding | 254 M | ||||
| Shares Owned By Insiders | 0.35 % | ||||
| Shares Owned By Institutions | 97.63 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 6.61 X | ||||
| Price To Sales | 10.04 X | ||||
| Revenue | 12.07 B | ||||
| Gross Profit | 6.44 B | ||||
| EBITDA | 4.97 B | ||||
| Net Income | 3.95 B | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 3.88 B | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 73.49 X | ||||
| Cash Flow From Operations | 3.63 B | ||||
| Short Ratio | 2.78 X | ||||
| Earnings Per Share | 15.32 X | ||||
| Price To Earnings To Growth | 2.52 X | ||||
| Target Price | 535.56 | ||||
| Number Of Employees | 6.4 K | ||||
| Beta | 0.32 | ||||
| Market Capitalization | 120.46 B | ||||
| Total Asset | 26.14 B | ||||
| Retained Earnings | 13.56 B | ||||
| Working Capital | 7.34 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
| Net Asset | 26.14 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.